Monograph Details
|
|
Cardiovascular System
> Hypertension
|
|
HYZAAR 50-12.5 |
| Manufacturer |
|
Merck & Co., Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Angiotensin II receptor blocker + diuretic. |
| Generic Name |
|
Losartan potassium 50mg, hydrochlorothiazide 12.5mg; tabs. |
| Also |
• HYZAAR 100-12.5
• HYZAAR 100-25
|
| Indications |
|
Hypertension (not for initial therapy unless HTN is severe). To reduce stroke in hypertensive patients with left ventricular hypertrophy (LVH); this benefit may not apply to black patients. |
| Children |
|
<18yrs: not recommended. |
| Adults |
|
≥18yrs: One 50–12.5mg tab once daily; may increase after about 3 weeks (2–4 weeks for severe HTN) to two 50–12.5mg tabs once daily or one 100–25mg tab once daily. Titrate components: see literature. HTN with LVH: switch from losartan monotherapy (see literature). Severe renal impairment (CrCl<30mL/min): not recommended. |
| Contraindications |
|
Anuria. Sulfonamide allergy. Pregnancy (Cat.D in 2nd and 3rd trimesters). |
| Precautions |
|
Hypovolemia. Hepatic impairment. Severe CHF (with hypotension or excess volume depletion by overdiuresis). Diabetes. Renal artery stenosis. Asthma. Postsympathectomy. SLE. Gout. Monitor electrolytes. May interfere with parathyroid tests. Elderly. Pregnancy (Cat.C in 1st trimester). Nursing mothers: not recommended. |
| Interactions |
|
Potentiates other antihypertensives, tubocurarine. Hypokalemia with corticosteroids, ACTH. Avoid K+ sparing diuretics, K+ supplements, K+ containing salt substitutes. Orthostatic hypotension with alcohol, other CNS depressants. May be antagonized by NSAIDS. May antagonize pressor amines (eg, norepinephrine). Adjust antihyperglycemics. May increase digitalis, lithium toxicity. |
| Adverse Reactions |
|
Dizziness, abdominal pain, palpitations, back pain, sinusitis, cough, upper respiratory infection, rash, hyperkalemia; angioedema, syncope (discontinue if occurs), rhabdomyolysis (rare). |
| How Supplied |
|
Tabs—30, 90, 1000 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
